Purpose: To evaluate the efficacy of a single intravitreal injection of ocriplasmin 125 μg across relevant subpopulations of patients with symptomatic vitreomacular adhesion (VMA)/vitreomacular traction (VMT), including when associated with macular hole.
Design: Two multicenter, randomized, placebo-controlled, double-masked, 6-month studies.
Participants: A total of 652 randomized patients (464 receiving ocriplasmin; 188 receiving placebo).
Methods: A single intravitreal injection of ocriplasmin 125 μg or placebo in the study eye.
Main outcome measures: Prespecified subgroup analyses were conducted to evaluate the effects on the proportion of patients with nonsurgical resolution of focal VMA at day 28, nonsurgical full-thickness macular hole (FTMH) closure at month 6, and categoric improvement in best-corrected visual acuity (BCVA) at month 6.
Results: Resolution of VMA at day 28 was achieved more often in younger patients (<65 years), eyes without epiretinal membrane, eyes with FTMH, phakic eyes, and eyes with a focal VMA ≤ 1500 μm. Eyes with FTMH width ≤ 250 μm were more likely to achieve nonsurgical FTMH closure. Categoric ≥ 2-line and ≥ 3-line improvement in BCVA occurred more often in younger patients (<65 years) and in patients with a lower baseline BCVA (<65 letters). Treatment differences in favor of ocriplasmin were generally observed across each subgroup of subpopulations studied.
Conclusions: Subgroup analyses confirmed the positive effect of ocriplasmin across relevant subpopulations.
Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.